EZH2 and neoplasm: When corrected for other predictive factors including age at diagnosis, tumour grade, tumour focality, and adjuvant therapy status in multivariate analysis, tumours with high EZH2 protein expression were significantly associated with poor 5-year PFS outcome, with a hazard ratio of 6.784 (95% confidence interval 1.465–31.421, p = 0.014).